Are Clovis Oncology, Inc. (CLVS) Shorts Feeling the Heat?

Clovis Oncology Inc (CLVS) option traders are optimistic after an FDA nod

Apr 7, 2015 at 10:56 AM
facebook X logo linkedin


Thanks to a regulatory nod, Clovis Oncology Inc (NASDAQ:CLVS) shot higher out of the gate, and was last seen flirting with a gain of 9% at $74.84. The stock is now up more than 33% in 2015, and while option traders are rolling the dice on even more short-term upside, short sellers may be shaking in their boots.

CLVS calls are trading at 11 times the average intraday clip, and have nearly doubled puts thus far. It looks like speculators are buying to open the April 75 call, amid hopes for the shares to extend their journey to well north of $75 by options expiration on Friday, April 17. In light of the equity's surge, delta on the call more than doubled overnight, to 0.49 from 0.21, implying a roughly 1-in-2 shot of the contract expiring in the money.

Today's appetite for bullish bets marks a shift in sentiment among CLVS' options crowd. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 50-day put/call volume ratio sits at an annual high of 1.39. In other words, option buyers have bought to open CLVS puts over calls at a much faster-than-usual pace during the past 10 weeks.

As alluded to earlier, CLVS shorts might be feeling the heat today. Short interest accounts for nearly 24% of the stock's total available float. In fact, it would take almost 12 sessions to repurchase these pessimistic positions, at the stock's average daily trading volume -- ample fuel for a short squeeze to propel CLVS even higher.

Thanks to today's rally -- fueled by a fresh "breakthrough" status for its ovarian cancer therapy by the Food and Drug Administration -- CLVS is poised to end atop its 10-day moving average for the first time since March 19, when the stock was two days off an annual high of $83.46. Elsewhere in the biotech world, this pair of drugmakers is on the rise in the wake of upbeat analyst attention, while dismal data is obliterating Ocular Therapeutix Inc (NASDAQ:OCUL).

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI